Conferences & Events

GAIN Arrhus, Denmark

GAIN: EnGAging an Interdisciplinary Team for NSCLC Diagnosis, Personalized Assessment, and Treatment

REGIONAL SUMMIT
Hosted by Comwell Aarhus

Wednesday, May 13, 2015
8:30 AM-3:15 PM

Comwell Aarhus
Værkmestergade 2, 8000 Aarhus, Denmark
+45 86 72 80 00

Philadelphia, PA 19111

Note - There is no cost to participate in this activity.
 
REGISTER NOW                    Download Flyer
 

GAIN is an interdisciplinary summit that seeks to address clinical gaps in the diagnosis and care of patients with locally advanced and metastatic non-small cell lung cancer (NSCLC).

The goal is to improve performance of a team of specialists who are responsible for appropriate staging, mediastinal lymph node assessment, tissue acquisition, biomarker analysis and immunotherapy in patients with NSCLC.

Summit Chair

Peter Meldgaard, MD, PhD
Clinical Associate Professor
Department of Clinical Medicine - The Department of Oncology
Aarhus University

Summit Steering Committee

Eric S. Edell, MD, FCCP (Co-chair)
Mayo Clinic

Septimiu Murgu, MD, FCCP (Co-chair)
The University of Chicago Medicine

Mari Mino-Kenudson, MD
Harvard Medical School

David S. Ettinger, MD
The Sidney Kimmel Comprehensive Cancer Center at
Johns Hopkins
 
Suresh S. Ramalingam, MD
Emory University School of Medicine
Winship Cancer Institute

All attendees participate in multidisciplinary, interactive small-group sessions, which include:
  • Case-based Tumor Board discussions
  • Mediastinal anatomy review and exercises
  • Simulated exercises to acquire tissue samples followed by slide preparation and interpretation
  • Analysis of pathological samples
  • Guided review of treatment-focused cases with participant decision making
At the conclusion of this activity, you should be able to:
  • Explain the mechanisms of immunotherapies that have been studied for NSCLC
  • Describe and demonstrate the cognitive knowledge or technical skills required to obtain an adequate tissue sample for NSCLC diagnosis and classification
  • Identify current biomarkers utilized to categorize molecular and histologic features of NSCLC and their relevant applications for diagnosis, monitoring, and personalized care
  • Identify a NSCLC coordinated care plan among interdisciplinary colleagues and develop a plan for implementation

Take part in this important educational initiative, and you will have the opportunity to earn CME credit and gain access to performance improvement activities developed by CHEST, the American Society for Clinical Pathology, the National Comprehensive Cancer Network® (NCCN®), IASLC and The France Foundation.

Accreditation Information

Physicians
The American College of Chest Physicians (CHEST) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CHEST designates this live activity for a maximum of 5.25 AMA PRA Category 1 Credits™. Individuals should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Provider-approved by the California Board of Registered Nursing, Provider Number 16433, for 5.25 contact hours.

In accordance with the Physician Payment Sunshine Act, manufacturers of pharmaceutical drugs and devices, as well as group purchasing organizations, must report payments or transfers of value (such as meals, honoraria, or travel reimbursements) made to US physicians.

Because meals are provided for this course, some manufacturers who provided support may require the reporting of information about physicians attending this course. If a manufacturer requests information, CHEST will provide your name, business address, specialty, NPI and license number, as well as the estimated individual value of your meals.

Please consider the above information prior to registering for this course.

Presented through an educational collaboration by CHEST, ASCP, the National Comprehensive Cancer Network® (NCCN®), IASLC, and The France Foundation.

We gratefully acknowledge the following for their financial support of GAIN 3.0:

  • Bristol-Myers Squibb
  • Genentech/Astellas
  • Merck
  • Lilly USA, LLC